NASDAQ:AIMT
Delisted
Aimmune Therapeutics Stock News
$34.49
+0 (+0%)
At Close: May 27, 2022
New PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented
8-K: Aimmune Therapeutics, Inc.
06:18am, Friday, 29'th May 2020
(EDGAR Online via COMTEX) --
false 0001631650 0001631650 2020-05-27 2020-05-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM...
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), ein biopharmazeutisches Unternehmen, das Behandlungsmethoden für lebensbedrohliche Nahrungsmittelallergien
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 (Aller
Xconomy: Insitro Adds $143M to Fuel Machine Learning-Driven Drug Development
02:13am, Wednesday, 27'th May 2020
A stem cell biologist, a gene editing expert, and a data engineer walk into a room...and that’s just a few of the people Daphne Koller has recruited in
Some Analysts Just Cut Their Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Estimates
10:18am, Tuesday, 19'th May 2020
The latest analyst coverage could presage a bad day for Aimmune Therapeutics, Inc. (NASDAQ:AIMT), with the analysts...
Why Are So Many Traders Betting Against the First Therapy for Peanut Allergies?
12:03pm, Saturday, 16'th May 2020
Short-sellers are convinced a company marketing the first approved biologic for treating peanut allergies in children and teenagers will fail. Here's why.
Edited Transcript of AIMT earnings conference call or presentation 11-May-20 8:30pm GMT
04:26pm, Tuesday, 12'th May 2020
Q1 2020 Aimmune Therapeutics Inc Earnings Call
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
12:00pm, Tuesday, 12'th May 2020
Aimmune Therapeutics to Present at the RBC Capital Markets 2020 Global Healthcare Conference
Is Aimmune Therapeutics (NASDAQ:AIMT) Weighed On By Its Debt Load?
11:16am, Tuesday, 12'th May 2020
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Aimmune Therapeutics Inc (AIMT) Q1 2020 Earnings Call Transcript
04:01am, Tuesday, 12'th May 2020
AIMT earnings call for the period ending March 31, 2020.
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q1 2020 Results - Earnings Call Transcript
03:44am, Tuesday, 12'th May 2020
Aimmune Therapeutics, Inc. (NASDAQ:AIMT) Q1 2020 Earnings Conference Call May 11, 2020 16:30 ET Company Participants DeDe Sheel - Vice President, Investor Relat
Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue Estimates
09:45pm, Monday, 11'th May 2020
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 10.44% and -67.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
08:05pm, Monday, 11'th May 2020
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
12:00am, Monday, 11'th May 2020
Aimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational Highlights
